The GLP-1 revolution brought unprecedented weight loss results, but now the research infrastructure is struggling to keep pace. More than 120 anti-obesity drugs are in active development, nearly double the trial volume from five years ago, and they are all competing for the same pool of qualified sites, trained investigators, and eligible patients.

The challenge goes beyond simple numbers. Obesity protocols require specialized equipment like DEXA scanners, structured lifestyle interventions, and multi-year cardiovascular follow-up. Site activation rates have dropped to roughly 62% in North America, meaning four in ten sites fail to enroll even a single patient. Meanwhile, commercial availability of semaglutide and tirzepatide has changed patient recruitment dynamics, as many eligible participants are already on effective therapy and reluctant to enter placebo-controlled trials.

Demographic representation remains an additional constraint. Despite clear mandates, White non-Hispanic participants continue to dominate enrollment while Black and Hispanic patients, who bear disproportionate disease burden, remain underrepresented. The FDA's 2024 draft guidance on Diversity Action Plans signals regulatory expectations are rising alongside trial volume, adding another layer of complexity to already strained feasibility planning.